EUCTR2016-002349-50-BE进行中（未招募）1 期
Phase I/II study with galunisertib (LY2157299) combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer and an activated TGF-ß signature
etherlands Cancer Institute- Antoni van Leeuwenhoek Hospital (NKI-AVL)0 个研究点目标入组 31 人开始时间: 2017年11月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Histological or cytological proof of CRC;
- •2. Disease progression or relapse upon first line of treatment (maximum lines of treatment is one for phase I and phase II of this study) for advanced CRC with fluoropyrimidine containing chemotherapy as single agent or in combination (combinations with oxaliplatin, irinotecan, bevacizumab and cetuximab/panitumumab are allowed);
- •3. Written documentation of activated TGF-ß signature-like gene signature, as determined by the validated assay of Agendia;
- •4. Age = 18 years;
- •5. Able and willing to give written informed consent;
- •6. WHO performance status of = 1;
- •7. LVEF = 55%;
- •8. Able and willing to undergo blood sampling for PK and PD analysis;
- •9. Able and willing to undergo tumor biopsies before start, during treatment and at the end of treatment
- •10. Life expectancy = 3 months allowing adequate follow up of toxicity evaluation and anti-tumor activity;
- •11. Evaluable disease according to RECIST 1.1 criteria (measurable disease for the phase II part; evaluable disease is sufficient for the phase I part);
- •12. Minimal acceptable safety laboratory values
- •a. ANC of = 1.5 x 109 /L
- •b. Platelet count of = 100 x 109 /L
- •c. Hepatic function as defined by serum bilirubin = 1.5 x ULN, ALAT and ASAT = 3.0 x ULN, or ALAT and ASAT = 5 x ULN in patients with liver metastases
- •d. Renal function as defined by serum creatinine =1.5 x ULN
- •e. Creatinine clearance = 50 ml/min (by Cockcroft-Gault formula or MDRD);
- •13. Negative pregnancy test (urine or serum) for female patients with childbearing potential.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 21
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Any treatment with investigational drugs within 30 days prior to receiving the first dose of investigational treatment;
- •2. Known or suspected dihydropirimidine dehydrogenase deficit (Mutant for DPD*2A genotype, 1236 GA genotype, 1679TG genotype and 2846A>T genotype);
- •3. Symptomatic or untreated leptomeningeal disease;
- •4. Symptomatic brain metastasis. Patients previously treated or untreated for these conditions that are asymptomatic in the absence of corticosteroid therapy are allowed to enrol. Brain metastasis must be stable with verification by imaging (e.g. brain MRI or CT (<21 days before start of treatment) completed at screening demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive enzyme inducing anti-epileptic drugs or corticosteroids;
- •5. History of cardiac disease, including myocardial infarction within 6 months before study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension, major cardiac abnormalities, a predisposition for developing aneurysms including family history of aneurysms, Marfan syndrome, bicuspid aortic valve, or evidence of damage to the large vessels of the heart.
- •6. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral galunisertib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection);
- •7. Woman who are pregnant or breast feeding;
- •8. Unreliable contraceptive methods. Both men and women enrolled in this trial must agree to use a reliable contraceptive method throughout the study (adequate contraceptive methods are: condom, sterilization, other barrier contraceptive measures preferably in combination with condoms);
- •9. Radio- or chemotherapy within the last 2 weeks prior to receiving the first dose of investigational treatment. Palliative radiation (1x 8Gy) is allowed;
- •10. Patients who have undergone any major surgery within the last 2 weeks prior to starting study drug or who would not have fully recovered from previous surgery;
- •11. Active infection requiring systemic antibiotics or uncontrolled infectious disease;
- •12. Patients with a known history of hepatitis B or C or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients;
- •13. Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for the study;
- •14. Known hypersensitivity to one of the study drugs or excipients.
研究者
相似试验
进行中（未招募）
1 期
Phase I/II studie met galunisertib combined with chemotherapy in patients with metastasized, resistent bowle cancer and an activated TGF-beta signature.colorectal carcinomaEUCTR2016-002349-50-NLetherlands Cancer Institute- Antoni van Leeuwenhoek Hospital (NKI-AVL)31
进行中（未招募）
1 期
Phase I/II study with galunisertib combined with chemotherapy in patients with metastasized, resistent bowle cancer and an activated TGF-beta signature.EUCTR2016-002349-50-ITTHE NETHERLANDS CANCER INSTITUTE31
撤回
2 期
Phase I/II study with galunisertib (LY2157299) combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer and an <br>activated TGF-* signature<br>bowel cancercolorectal carcinoma10017991NL-OMON46888Antoni van Leeuwenhoek Ziekenhuis10
进行中（未招募）
1 期
Phase I/II study with galunisertib combined with chemotherapy in patients with metastasized, resistent bowle cancer and an activated TGF-beta signature.colorectal carcinomaEUCTR2016-002349-50-ESetherlands Cancer Institute- Antoni van Leeuwenhoek Hospital (NKI-AVL)31
招募中
2 期
Phase I/II study with galunisertib combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer with peritoneal metastasesNL-OMON53340Antoni van Leeuwenhoek Ziekenhuis31